Moreover, given the observed decline in the expression of CYP27B1, VDR, CYP11A1, and RORα/γ during cancer progression, as previously discussed, the utility of VD-based treatments may be confined to early rather than advanced stages of the disease [30]. The gene discussed is VDR; the disease is cancer.